Pharmaceutical Technology Europe, Jan 7, 2011 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, Jan 7, 2011
Special Feature
An Update On The EU's Plans For Excipient Regulation
By Iain Moore
Iain Moore explains what progress has been made so far regarding EU plans to regulate excipients.
Is There A Need For Stringent Regulations For Excipients?
By Michael Cooke
Excipients should be regulated to manage risk. Although, excipients are an integral part of a finished pharmaceutical product, the issue of regulation is complex.
The Growth Of ODTs
By Liesbeth Meeus
Orally disintegrating tablets (ODTs) are growing in popularity and their market value could exceed $13 billion in sales by 2015, based on current global growth trends.
Using Excipients In Powder Formulations
By Oliver Luhn
During the past few years, we've seen a growing interest in direct oral application products, evidenced by the large amount of products already available on the market.
Using Excipients With Biologics
By Sophie Chesnoy
Biologics are large molecular weight molecules primarily formulated for parenteral administration; however, there are some smaller biomolecules that have been formulated for oral use.
Printable Medicines: A Microdosing Device For Producing Personalized Medicines
By Johannes G. Khinast , Andreas Zimmer , Guenter Brenn , Wolfgang Bauer , Bernhard Eitzinger , Daniela Strohmeier , Nina Schroedl , Michael M. Gruber , Christine Voura
The authors describe a new method for the production of personalised medicines utilising ultra-precise microdrop printing technology.
The role of sterile filtration in the biopharm industry
By Maik W. Jornitz
Biopharmaceuticals commonly cannot be terminally sterilised, as such aseptic processing using sterilising grade filtration is essential.
Ask the Expert
The Use Of UHPLC In Post-Drug Development
By Sergio Guazzotti
UHPLC offers increased performance compared with HPLC, including shorter analysis times and increased sensitivity.
Industry Insider
Will DTC Advertising Appear In Europe?
By Nathan Jessop
Direct-to-consumer (DTC) advertising is firmly entrenched in the US, but has historically been considered as an inappropriate means of communication in Europe for prescription-only medicines.
How innovation is cushioning pharma's fall from the patent cliff.
Editor's Comment
Should We Back DTC in Europe?
By Fedra Pavlou
This month, our columnist Nathan Jessop discusses a topic that remains highly debated in Europe; direct to consumer (DTC) advertising.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here